Zeenat Bhat, MD
Nephrology · Ann Arbor, MINPI 1669614244
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $98 of the $110 with a category attached, or 88.9%. 5 manufacturers reported payments, led by Ultragenyx Pharmaceutical Inc. at 32.2% of the total. Reporting peaked in 2020 at $45 and has fallen 73.2% since, to $12 in 2022. That places this record below the midpoint for nephrology clinicians in MI, where the typical reported total is $606.
Across 7 payments — averaging $15.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ultragenyx Pharmaceutical Inc.$35
- GSK$28
- Otsuka America Pharmaceutical, Inc.$18
- Fresenius USA Marketing, Inc.$17
- Vifor Pharma, Inc.$12
Across 53 payments — averaging $11,164 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$338K
- Vertex$138K
- Travere Therapeutics, Inc.$51K
- Sanofi$45K
- Biogen$19K
What the payments were for
- Food & beverage$9889%
- Education$1211%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ultragenyx Pharmaceutical Inc. | 2 | $35 |
| GSK | 2 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Fresenius USA Marketing, Inc. | 1 | $17 |
| Vifor Pharma, Inc. | 1 | $12 |
How this compares
$110 in reported general payments places this provider in the 15th percentile of 325 nephrology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydralazine Hcl | 13 | $759 |
| Tacrolimus | 12 | $595 |
| Calcitriol | 23 | $323 |
| Amlodipine Besylate | 24 | $286 |
| Prednisone | 24 | $135 |
| Losartan Potassium | 19 | $76 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Ann Arbor
- Alexander YevzlinAnn Arbor$1.1M
- Laura MarianiAnn Arbor$150K
- Matthias KretzlerAnn Arbor$70K
- Lenar YessayanAnn Arbor$40K
- Bruce RobinsonAnn Arbor$38K
- Karthik RamaniAnn Arbor$27K
- Rajiv SaranAnn Arbor$23K
- Panduranga RaoAnn Arbor$20K
- Andrea OliverioAnn Arbor$15K
- Abhijit NaikAnn Arbor$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.